(Length of Discussion: 10 min)

Edward (Ted) Schaeffer, MD, Ph.D. and Alicia Morgans, MD share a dynamic discussion on the risk strategy that may be employed for high-risk prostate cancer patients including oligometastatic disease.  

They share observations such as an increase in patient volume in their clinics of men with rising PSAs, high grade and locally advanced disease.  In discussing the best way to optimize the treatment in these men, they highlight the value of a multidisciplinary approach in evaluating their comorbidities, current disease state, and appropriate referral for genetic counseling when available.  

They dive further into a candid discussion on imaging technologies specifically PSMA Gallium 68, F18 and Axumin®.  Closing on clinical trial opportunities and how to continue to advance our understanding of these treatment strategies.


Biographies:
Edward Schaeffer, MD, Ph.D. is Chair of the Department of Urology at Feinberg School of Medicine and Program Director of the Genitourinary Oncology Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Schaeffer is an Edmund Andrews Professor of Urology and his clinical and research focus is the diagnosis and treatment of men with prostate cancer. 

Alicia Morgans, MD, MPH